Why Swedish Orphan Biovitrum stock moves
Swedish Orphan Biovitrum rose sharply, without company news.
Written after the close on ·
Why today
16,413 news analyzed todaySwedish Orphan Biovitrum rose sharply, without company news.
Swedish Orphan Biovitrum rose, while the market fell slightly, so the move ran against the broader market.
No company news from that session clearly explains the jump.
Over the last five trading days the shares rose slightly, a little more than the market.
Short positions fell over the last few sessions, which is background only.
Today's move of +2.28% was 2.1 times a normal day's 1.1%. OMX Stockholm 30 moved −0.32% on the same day.
Swedish Orphan Biovitrum +2.28%OMX Stockholm 30 −0.32%Against the market
What analysts expect, and how often they have been right
Analysts’ estimates for Swedish Orphan Biovitrum.
Swedish Orphan Biovitrum earned more than expected in 7 out of 8 reports.
For comparison, about 46% of reports from Nordic companies beat the estimate in the last three years.
The share moved in the same direction as the earnings surprise in 4 out of 8 reports with a measured move, against about 63% of reports from Nordic companies.
Ratings
Price targets
Latest price 498.20 SEK
Earnings against expectations, and the share’s reaction
Expected EPSAbove estimateBelow estimateAs expectedSEK
Next reported quarter: expected earnings per share of 5.72 SEK (February 4). For the current fiscal year, expected earnings per share changed from 19.37 SEK three months ago to 20.68 SEK now. 2026 estimate: 20.68 SEK. 2027 estimate: 23.68 SEK. People on the board and in management must report their trades in the share to Finansinspektionen, Sweden's financial supervisor. October 30: Sell about 20 m SEK. July 29: Sell about 37 m SEK. July 28: Sell about 46 m SEK. July 28: Sell about 46 m SEK. July 28: Sell about 22 m SEK.
Has the share price followed the business?
Price and earnings moved in the same direction: 1 out of 3 years. Across Nordic companies, that happens in about 60% of years. In 2025, the price changed +5% and earnings per share went from 11.24 SEK to 1.37 SEK.
Revenue, profit and market cap
RevenueProfitMarket capHatched bars: analysts’ estimates.bn SEK
Assets, liabilities and market cap
AssetsLiabilitiesMarket capbn SEK
Price and earnings moved in the same direction: 1 out of 3 years.Market cap (Now): 173.4 bn SEKRevenue 2025: 28.2 bn SEK
What the key figures say about Swedish Orphan Biovitrum
The figures connect what Swedish Orphan Biovitrum earns with what investors pay.
The line shows the share price in the same year, on its own scale. Hatched bars: analysts’ estimates.
Profit divided by the number of shares. Each share represents this much of the earnings.
2022–2025: 1.37 SEK–11.24 SEK. Peers: Zoetis $5.88, Lundbeck 3.92 DKK, Hims & Hers Health -$0.64. 2026 estimate: 20.68 SEK (19.70 SEK–22.02 SEK). 2027 estimate: 23.68 SEK (19.23 SEK–27.53 SEK).
What the company sold during the year.
2022–2025: 18.8 bn SEK–28.2 bn SEK. Peers: Zoetis $9.5B, Lundbeck 26.0 bn DKK, Hims & Hers Health $2.6B. 2026 estimate: 33.7 bn SEK (33.3 bn SEK–34.1 bn SEK). 2027 estimate: 38.1 bn SEK (35.5 bn SEK–42.1 bn SEK).
The percentage of revenue left after the costs of running the business.
2022–2025: 3.3%–21.6%. Peers: Zoetis 37.4%, Lundbeck 21.8%, Hims & Hers Health −6.0%.
Profit as a percentage of shareholders’ money in the company.
2022–2025: 1.3%–9.9%. Peers: Zoetis 57.6%, Lundbeck 15.4%, Hims & Hers Health −32.0%.
The price investors pay for each unit of annual earnings per share. Not shown for a loss.
2022–2025: 24.4–242.9. Peers: Zoetis 13.5, Lundbeck 14.3. 2026 estimate: 24.1. 2027 estimate: 21.0.
What investors pay for each unit the company sells.
2022–2025: 3.40–4.19. Peers: Zoetis 3.40, Lundbeck 2.14, Hims & Hers Health 2.35. 2026 estimate: 5.14. 2027 estimate: 4.55.
Net debt divided by operating earnings before depreciation and amortisation.
2022–2025: 0.96–2.70. Peers: Zoetis 1.92, Lundbeck 0.87.
More key figures
Market cap divided by shareholders’ equity, what remains after liabilities.
2022–2025: 2.41–3.05. Peers: Zoetis 9.80, Lundbeck 2.06, Hims & Hers Health 18.72.
Market cap plus net debt, divided by operating earnings. This includes debt.
2022–2025: 18.9–150.1.
Cash left after investments, divided by the number of shares.
2022–2025: -1.39 SEK–15.66 SEK. Peers: Zoetis $5.61, Lundbeck 5.20 DKK, Hims & Hers Health $0.26.
The percentage of assets financed by shareholders’ equity.
2022–2025: 45.7%–55.9%.
What to watch next, and why
The earnings report shows how Swedish Orphan Biovitrum's revenue and profit have changed.
- Earnings report
The earnings report shows how Swedish Orphan Biovitrum's revenue and profit have changed.
Add to calendar
More about Swedish Orphan Biovitrum
Insider trades
People on the board and in management must report their trades in the share to Finansinspektionen, Sweden's financial supervisor.
- Daniel Rankin, senior executiveSellabout 20 m SEK
- Guido Oelkers, CEOSellabout 37 m SEK
- Duane Barnes, senior executiveSellabout 46 m SEK
- Guido Oelkers, CEOSellabout 46 m SEK
- Christin Wesström, senior executiveSellabout 22 m SEK
Earnings report
Next report: · Add to calendar · Google Calendar
On its last 15 report days Swedish Orphan Biovitrum usually moved about 3.4%. On a normal day it moves 1.1%.
+1.09% Why? +2.15% +1.20% +7.98%
10,000 SEK in Swedish Orphan Biovitrum bought on November 7, 2016 is worth 52,900 SEK today, with dividends reinvested.
What would 10,000 SEK in Swedish Orphan Biovitrum be worth today? →
What would 10,000 SEK in Swedish Orphan Biovitrum be worth today?
52,900 SEK
with dividends reinvested, bought on November 7, 2016.
The five biggest days of the journey
· +25.8% · the whole market rose 0.8% the same day
· −24.3% · the whole market fell 1.0% the same day
· −17.9% · the whole market fell 0.1% the same day
· +16.5% · the whole market rose 0.3% the same day
· −14.5% · the whole market fell 0.7% the same day
Earlier days
+1.63% market −0.11% Swedish Orphan Biovitrum rose slightly over the week, while the broader market was roughly flat. Read →
Swedish Orphan Biovitrum rose slightly over the week, while the broader market was roughly flat.
The move was ordinary in size, with trading around its usual level.
The latest quarterly report on 27 October beat expectations, with revenue up 16 per cent at constant exchange rates.
Short sellers, who bet on a share price fall, trimmed their reported positions in early November.
+1.09% market +0.83% Swedish Orphan Biovitrum rose, moving in line with the market. Read →
Swedish Orphan Biovitrum rose, moving in line with the market.
No company news from the last session explains the move.
Over the last five trading days the stock rose slightly, in line with OMX Stockholm 30.
Earlier, Q3 2026 results beat expectations, with revenue up 16 per cent at constant exchange rates and the revenue growth outlook raised.
The move was within its usual daily range, so it was an ordinary day for the stock.
−2.24% market +0.48% Swedish Orphan Biovitrum fell sharply. Read →
Swedish Orphan Biovitrum fell sharply.
No company news from that session explains the move, so the cause is unclear.
Over the last five trading days the stock rose clearly, moving more than OMX Stockholm 30.
Its strong third-quarter report, with revenue up 16 per cent at constant exchange rates, came out before that session and beat expectations.
Investors may have taken profits after the earlier gains, which is a common pattern for a stock that has risen a lot.
+0.45% market −0.29% Swedish Orphan Biovitrum rose without a company-news explanation. Read →
Swedish Orphan Biovitrum rose without a company-news explanation.
Over the same day, OMX Stockholm 30 fell slightly, so the stock moved against the market.
The move was an ordinary-sized day for the stock.
Over the last five trading days, the stock rose sharply and clearly outpaced the market.
The likeliest backdrop is the strong third-quarter report, where revenue grew 16 per cent and earnings beat expectations, plus raised full-year revenue growth guidance.
+7.93% market +3.01% Swedish Orphan Biovitrum rose sharply over the week, a very big move for the stock. Read →
Swedish Orphan Biovitrum rose sharply over the week, a very big move for the stock.
The main driver was its third-quarter report on 27 October, which beat expectations, with total revenue up 16 per cent at constant exchange rates.
Sales of its blood-disorder medicines grew strongly, likely helping the shares.
Over the same days the OMX Stockholm 30 index rose clearly, so the stock moved more than the market.
+3.06% market +0.33% Swedish Orphan Biovitrum rose on strong quarterly results. Read →
Swedish Orphan Biovitrum rose on strong quarterly results.
Its share price rose sharply in the last session, on heavy trading of about three times a normal day, while the OMX Stockholm 30 index rose only slightly, so the stock clearly outpaced the market.
The likely driver is the third quarter 2026 report, published yesterday before the session opened, where total revenue grew 16 per cent at constant exchange rates and earnings per share beat expectations.
Raised full-year revenue growth guidance, the company's forecast for the year, to high-teens to low-20s per cent, probably added to the buying.
+1.09% market +0.96% Swedish Orphan Biovitrum rose strongly after its third-quarter results beat expectations. Read →
Swedish Orphan Biovitrum rose strongly after its third-quarter results beat expectations.
The move matched the broader market, with OMX Stockholm 30 also rising clearly.
Trading volume was about three times a normal session, and the move was within its usual daily range.
Revenue grew 16 per cent at constant exchange rates, driven by Haematology products such as Altuvoct and Doptelet.
Earnings per share also came in above last year, and management raised its full-year revenue growth outlook.
+0.49% market +0.41% Swedish Orphan Biovitrum rose slightly, moving in line with the market. Read →
Swedish Orphan Biovitrum rose slightly, moving in line with the market.
No company news explains the move clearly.
Over the last five trading days the shares rose clearly while OMX Stockholm 30 fell sharply, so the stock moved against the market.
Trading volume was well above its usual level, and the move was an ordinary size for the stock.
Earlier news on Tryngolza, a drug that could lift sales, likely supports investor interest.
+4.08% market −3.67% Swedish Orphan Biovitrum rose clearly over the last five trading days while the broader Stockholm market fell sharply. Read →
Swedish Orphan Biovitrum rose clearly over the last five trading days while the broader Stockholm market fell sharply.
Trading was heavier than usual, with volume around twice a normal session, suggesting more investors were active in the shares.
The news flow in the period was thin, and the most identifiable item came before the window, an analyst-style piece about the Tryngolza drug, which could partly explain renewed interest.
The next event to watch is the earnings report on Tuesday 27 October, which investors will use to judge the company's sales and profit outlook.
+2.64% market +0.17% Swedish Orphan Biovitrum rose sharply; no company news explains it. Read →
Swedish Orphan Biovitrum rose sharply; no company news explains it.
Swedish Orphan Biovitrum rose sharply in the last session while the market was roughly flat.
No company news from that session explains the move.
Over the last five trading days it rose sharply, against a slight fall in the OMX Stockholm 30.
That is a big move for this stock, about twice its usual five-day swing.
+2.15% market −0.89% Swedish Orphan Biovitrum rose sharply while the market fell. Read →
Swedish Orphan Biovitrum rose sharply while the market fell.
The stock rose sharply in the last session while OMX Stockholm 30 fell clearly.
No company news from the last session explains the move.
The stock rose clearly over the last five trading days while the index fell slightly.
Earlier news about a Tryngolza backing, and an earnings preview expecting a decline, came before the session.
−1.09% market +1.25% Swedish Orphan Biovitrum fell clearly, against a rising market. Read →
Swedish Orphan Biovitrum fell clearly, against a rising market.
No company news from that session explains it.
Over the last five trading days it rose slightly, a little more than OMX Stockholm 30, which also rose slightly.
Earlier news included a positive reimbursement backing for Tryngolza, a drug, on Thursday and last week, and analysts expect third-quarter earnings to decline, which could weigh on sentiment.
Trading volume was around its usual level, so the drop looks like ordinary selling rather than a thin-market move.
+2.39% market −0.02% Swedish Orphan Biovitrum rose sharply while the broader market was roughly flat. Read →
Swedish Orphan Biovitrum rose sharply while the broader market was roughly flat.
The most likely reason is the news that the UK's National Institute for Health and Care Excellence (NICE, the body that decides whether the NHS pays for a drug) backed Tryngolza, a treatment for a rare fat-metabolism disorder, which lifts the outlook for its sales.
Earlier this week, analysts expected third-quarter earnings to decline, which likely weighed on sentiment before the rebound.
Over the last five trading days the shares rose slightly, a smaller move than the market's slight gain.
The next thing to watch is the earnings report due Tuesday 27 October 2026, which will show whether sales of its rare-disease drugs are holding up.
Learn more · Why do stocks go up and down?